SCHEMBL24253713

SCHEMBL24253713

O=C1CCCC2(CCN(c3nc4ccc(C(F)(F)F)cc4o3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 6/20 0.42
HCRTR2 O43614 6/20 0.42
CNR2 P34972 1/20 0.37
PTGES O14684 2/20 0.34
GPR119 Q8TDV5 2/20 0.33
ADRA1B P35368 1/20 0.32
TRPV1 Q8NER1 1/20 0.31
ALDH1A1 P00352 2/20 0.31
USP2 O75604 1/20 0.31
LMNA P02545 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HPGD P15428 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
ADRA1A P35348 1/20 0.31
KCNH2 Q12809 1/20 0.31
NPY5R Q15761 1/20 0.31
MEN1 O00255 1/20 0.31
TSHR P16473 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30423555 1.00 HCRTR1 (0.42) HCRTR1HCRTR2CNR2PTGESGPR119
SCHEMBL24253843 0.80 AOC3 (0.34) HCRTR1HCRTR2GPR119ADRA1BALDH1A1
SCHEMBL30424819 0.80 AOC3 (0.34) HCRTR1HCRTR2GPR119ADRA1BALDH1A1
SCHEMBL30423539 0.75 KMT2A (0.41) HCRTR1HCRTR2ALDH1A1KMT2A
SCHEMBL24253712 0.75 KMT2A (0.41) HCRTR1HCRTR2ALDH1A1KMT2A
SCHEMBL24253729 0.74 HCRTR1 (0.49) HCRTR1HCRTR2LMNAKCNH2RAD51
SCHEMBL30423954 0.74 HCRTR1 (0.49) HCRTR1HCRTR2LMNAKCNH2RAD51
SCHEMBL24253533 0.73 LMNA (0.35) HCRTR1HCRTR2LMNAKCNH2RAD51
SCHEMBL24253721 0.73 RAD51 (0.32) HCRTR1HCRTR2KCNH2RAD51
SCHEMBL30424161 0.73 LMNA (0.35) HCRTR1HCRTR2LMNAKCNH2RAD51

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 HCRTR1 2245/4885HCRTR2 3027/4885CNR2 798/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 HCRTR1 2245/4885HCRTR2 3027/4885CNR2 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.